The Department of Defense has awarded the North American Clinical Trials Network of the Christopher & Dana Reeve Foundation a $2 million grant for research on the treatment of spinal cord injuries, according to a R&D report. NACTN, a collaboration of university neurosurgical teams, is led by Robert Grossman, MD, a professor of neurosurgery at The Methodist Hospital Neurosurgical Institute in Houston.
The funding will support Phase 2 and 3 trials of the drug Riluzole, an FDA-approved neuroprotective drug. Riluzole is designed to limit spinal cord damage.
More Articles on Spine:
NASS Advocacy Documentary Calls for More Spine Specialist Involvement
2 Laser Spine Institute Studies on Lumbar Spinal Stenosis Treatments Published
6 Opportunities for Spine Surgeons to Forward the Field
The funding will support Phase 2 and 3 trials of the drug Riluzole, an FDA-approved neuroprotective drug. Riluzole is designed to limit spinal cord damage.
More Articles on Spine:
NASS Advocacy Documentary Calls for More Spine Specialist Involvement
2 Laser Spine Institute Studies on Lumbar Spinal Stenosis Treatments Published
6 Opportunities for Spine Surgeons to Forward the Field